from TetraKit Technologies
September 12, 2023
Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.
Please reach out if you want to hear more about our platform technology.
September 9, 2023
Thank you European Association of Nuclear Medicine (EANM) for choosing our talk as a highlight session for this year.
You are invited to the Tuesday morning session, where Dr. Umberto Maria Battisti will present our universal labeling platform and its application to develop radiopharmaceuticals labeled with 18F and 211At.
The talk will take place on Tuesday, September 12th, from 09:45 to 11:15 at the M2M Track.
We hope to see you there.
September 7, 2023
We are pleased to announce that Dr. Umberto Maria Battisti, the COO and co-founder of TetraKit Technologies, will be speaking at the European Association of Nuclear Medicine (EANM) 23. During the speech, he will highlight the inventive application of our platform in creating next-generation theranostics with the use of 211At.
We are excited to have you join us on this special occasion.
Chief Executive Officer
“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”
Chief Scientific Officer
“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”